

Non-Insulin Therapies for Diabetes-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

https://marketpublishers.com/r/NE82CD5D01CMEN.html

Date: May 2018 Pages: 137 Price: US\$ 3,680.00 (Single User License) ID: NE82CD5D01CMEN

Abstracts

Report Summary

Non-Insulin Therapies for Diabetes-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Non-Insulin Therapies for Diabetes industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Non-Insulin Therapies for Diabetes 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Non-Insulin Therapies for Diabetes worldwide and market share by regions, with company and product introduction, position in the Non-Insulin Therapies for Diabetes market

Market status and development trend of Non-Insulin Therapies for Diabetes by types and applications

Cost and profit status of Non-Insulin Therapies for Diabetes, and marketing status Market growth drivers and challenges

The report segments the global Non-Insulin Therapies for Diabetes market as:

Global Non-Insulin Therapies for Diabetes Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):



North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia, Spain and Benelux) Asia Pacific (China, Japan, India, Southeast Asia and Australia) Latin America (Brazil, Argentina and Colombia) Middle East and Africa

Global Non-Insulin Therapies for Diabetes Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alpha-glucosidase Inhibitors Amylin Agonists Biguanides Dipeptidyl Peptidase-4 (DPP4) Inhibitors Glinides / Meglitinides GLP-1 Analogs / GLP-1 Agonists Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Sulfonylureas Thiazolidinediones Others

Global Non-Insulin Therapies for Diabetes Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmacy Retail Pharmacies Online Pharmacy Others

Global Non-Insulin Therapies for Diabetes Market: Manufacturers Segment Analysis (Company and Product introduction, Non-Insulin Therapies for Diabetes Sales Volume, Revenue, Price and Gross Margin):

GSK Eli Lilly Sumitomo Dainippon Pharma Intarcia Therapeutics Servier Jiangsu Hansoh Pharmaceutical



Novo Nordisk Emisphere Uni-Bio Science Group Takeda 3SBio Merck Dong-A Pharmaceutical Luye Pharma Group Eurofarma Geropharm Alkem Labs SatRx Pfizer Jiangsu Hengrui Medicine

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF NON-INSULIN THERAPIES FOR DIABETES

- 1.1 Definition of Non-Insulin Therapies for Diabetes in This Report
- 1.2 Commercial Types of Non-Insulin Therapies for Diabetes
- 1.2.1 Alpha-glucosidase Inhibitors
- 1.2.2 Amylin Agonists
- 1.2.3 Biguanides
- 1.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
- 1.2.5 Glinides / Meglitinides
- 1.2.6 GLP-1 Analogs / GLP-1 Agonists
- 1.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
- 1.2.8 Sulfonylureas
- 1.2.9 Thiazolidinediones
- 1.2.10 Others
- 1.3 Downstream Application of Non-Insulin Therapies for Diabetes
 - 1.3.1 Hospital Pharmacy
 - 1.3.2 Retail Pharmacies
 - 1.3.3 Online Pharmacy
 - 1.3.4 Others
- 1.4 Development History of Non-Insulin Therapies for Diabetes
- 1.5 Market Status and Trend of Non-Insulin Therapies for Diabetes 2013-2023

1.5.1 North America Non-Insulin Therapies for Diabetes Market Status and Trend 2013-2023

1.5.2 Regional Non-Insulin Therapies for Diabetes Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Non-Insulin Therapies for Diabetes in North America 2013-20172.2 Consumption Market of Non-Insulin Therapies for Diabetes in North America by Regions

2.2.1 Consumption Volume of Non-Insulin Therapies for Diabetes in North America by Regions

2.2.2 Revenue of Non-Insulin Therapies for Diabetes in North America by Regions 2.3 Market Analysis of Non-Insulin Therapies for Diabetes in North America by Regions

2.3.1 Market Analysis of Non-Insulin Therapies for Diabetes in United States 2013-2017



2.3.2 Market Analysis of Non-Insulin Therapies for Diabetes in Canada 2013-2017

2.3.3 Market Analysis of Non-Insulin Therapies for Diabetes in Mexico 2013-2017

2.4 Market Development Forecast of Non-Insulin Therapies for Diabetes in North America 2018-2023

2.4.1 Market Development Forecast of Non-Insulin Therapies for Diabetes in North America 2018-2023

2.4.2 Market Development Forecast of Non-Insulin Therapies for Diabetes by Regions 2018-2023

CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole North America Market Status by Types

3.1.1 Consumption Volume of Non-Insulin Therapies for Diabetes in North America by Types

3.1.2 Revenue of Non-Insulin Therapies for Diabetes in North America by Types

- 3.2 North America Market Status by Types in Major Countries
- 3.2.1 Market Status by Types in United States
- 3.2.2 Market Status by Types in Canada
- 3.2.3 Market Status by Types in Mexico

3.3 Market Forecast of Non-Insulin Therapies for Diabetes in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Non-Insulin Therapies for Diabetes in North America by Downstream Industry

4.2 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in Major Countries

4.2.1 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in United States

4.2.2 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in Canada

4.2.3 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in Mexico

4.3 Market Forecast of Non-Insulin Therapies for Diabetes in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES

Non-Insulin Therapies for Diabetes-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data



5.1 North America Economy Situation and Trend Overview

5.2 Non-Insulin Therapies for Diabetes Downstream Industry Situation and Trend Overview

CHAPTER 6 NON-INSULIN THERAPIES FOR DIABETES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

6.1 Sales Volume of Non-Insulin Therapies for Diabetes in North America by Major Players

6.2 Revenue of Non-Insulin Therapies for Diabetes in North America by Major Players

6.3 Basic Information of Non-Insulin Therapies for Diabetes by Major Players

6.3.1 Headquarters Location and Established Time of Non-Insulin Therapies for Diabetes Major Players

6.3.2 Employees and Revenue Level of Non-Insulin Therapies for Diabetes Major Players

6.4 Market Competition News and Trend

- 6.4.1 Merger, Consolidation or Acquisition News
- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

CHAPTER 7 NON-INSULIN THERAPIES FOR DIABETES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 GSK

- 7.1.1 Company profile
- 7.1.2 Representative Non-Insulin Therapies for Diabetes Product

7.1.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of GSK

7.2 Eli Lilly

7.2.1 Company profile

7.2.2 Representative Non-Insulin Therapies for Diabetes Product

7.2.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Eli Lilly

7.3 Sumitomo Dainippon Pharma

- 7.3.1 Company profile
- 7.3.2 Representative Non-Insulin Therapies for Diabetes Product

7.3.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Sumitomo Dainippon Pharma



7.4 Intarcia Therapeutics

7.4.1 Company profile

7.4.2 Representative Non-Insulin Therapies for Diabetes Product

7.4.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Intarcia Therapeutics

7.5 Servier

7.5.1 Company profile

7.5.2 Representative Non-Insulin Therapies for Diabetes Product

7.5.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Servier

7.6 Jiangsu Hansoh Pharmaceutical

7.6.1 Company profile

7.6.2 Representative Non-Insulin Therapies for Diabetes Product

7.6.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Jiangsu Hansoh Pharmaceutical

7.7 Novo Nordisk

7.7.1 Company profile

7.7.2 Representative Non-Insulin Therapies for Diabetes Product

7.7.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Novo Nordisk

7.8 Emisphere

7.8.1 Company profile

7.8.2 Representative Non-Insulin Therapies for Diabetes Product

7.8.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Emisphere

7.9 Uni-Bio Science Group

7.9.1 Company profile

7.9.2 Representative Non-Insulin Therapies for Diabetes Product

7.9.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Uni-Bio Science Group

7.10 Takeda

7.10.1 Company profile

7.10.2 Representative Non-Insulin Therapies for Diabetes Product

7.10.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Takeda

7.11 3SBio

7.11.1 Company profile

7.11.2 Representative Non-Insulin Therapies for Diabetes Product

7.11.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of



3SBio

7.12 Merck

7.12.1 Company profile

7.12.2 Representative Non-Insulin Therapies for Diabetes Product

7.12.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Merck

7.13 Dong-A Pharmaceutical

7.13.1 Company profile

7.13.2 Representative Non-Insulin Therapies for Diabetes Product

7.13.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of

Dong-A Pharmaceutical

7.14 Luye Pharma Group

7.14.1 Company profile

7.14.2 Representative Non-Insulin Therapies for Diabetes Product

7.14.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of

Luye Pharma Group

7.15 Eurofarma

7.15.1 Company profile

7.15.2 Representative Non-Insulin Therapies for Diabetes Product

7.15.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of

Eurofarma

- 7.16 Geropharm
- 7.17 Alkem Labs
- 7.18 SatRx
- 7.19 Pfizer
- 7.20 Jiangsu Hengrui Medicine

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES

- 8.1 Industry Chain of Non-Insulin Therapies for Diabetes
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES

- 9.1 Cost Structure Analysis of Non-Insulin Therapies for Diabetes
- 9.2 Raw Materials Cost Analysis of Non-Insulin Therapies for Diabetes



- 9.3 Labor Cost Analysis of Non-Insulin Therapies for Diabetes
- 9.4 Manufacturing Expenses Analysis of Non-Insulin Therapies for Diabetes

CHAPTER 10 MARKETING STATUS ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
- 10.2.1 Pricing Strategy
- 10.2.2 Brand Strategy
- 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Non-Insulin Therapies for Diabetes-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: https://marketpublishers.com/r/NE82CD5D01CMEN.html

Price: US\$ 3,680.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/NE82CD5D01CMEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Non-Insulin Therapies for Diabetes-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data